Fluticasone furoate versus placebo in symptoms of grass-pollen allergic rhinitis induced by exposure in the Vienna Challenge Chamber

References

• Day JH, Horak F, Briscoe MP, . The role of allergen challenge chambers in the evaluation of anti-allergic medication: an international consensus paper. Clin Exp Allergy Reviews 2006;6: 31–59
   Google Scholar
• Horak F, Jäger S. The Vienna Challenge Chamber – a new method of allergy exposure tests. Wien Klin Wochenschr 1987;99: 509–10
   Web of Science ®Google Scholar
• Day JH, Briscoe M, Rafeiro E, . Comparative onset of action and symptom relief with cetirizine, loratadine or placebo in an environmental exposure unit in subjects with seasonal allergic rhinitis: confirmation of a test system. Ann Allergy Asthma Immunol 2001;87: 474–81
   PubMed Web of Science ®Google Scholar
• Zieglmayer UP, Horak F, Toth J, . Efficacy and safety of an oral formulation of cetirizine and prolonged release pseudoephedrine versus budesonide nasal spray in the management of nasal congestion in allergic rhinitis. Treat Resp Med 2005;4: 283–7
   PubMedGoogle Scholar
• Horak F, Toth J, Marks B, . Efficacy and safety relative to placebo of an oral formulation of cetirizine and sustained-release pseudoephedrine in the management of nasal congestion. Allergy 1998;53: 849–56
   PubMed Web of Science ®Google Scholar
• Valotis A, Högger P. Human receptor kinetics and tissue affinity of the enhanced affinity glucocorticoid fluticasone furoate (GW 685698X). Conference of the European Academy of Allergology and Clinical Immunology (EAACI). Austria: Vienna10–14 June2006[Abstract No. 780]
   Google Scholar
• Salter M, Biggadike K, Clackers M, . Fluticasone furoate (GW 685698X)-enhanced affinity for the glucocorticoid receptor: cellular and in vivo pharmacology. Conference of the European Academy of Allergology and Clinical Immunology (EAACI). Austria: Vienna10–14 June2006[Abstract No. 781]
   Google Scholar
• Biggadike K, Bledsoe R, Hassell A, . Fluticasone furoate (GW 685698X)-enhanced affinity for the glucocorticoid receptor: receptor crystal structure and route of metabolic inactivation. Conference of the European Academy of Allergology and Clinical Immunology (EAACI). Austria: Vienna10–14 June2006[Abstract No. 783]
   Google Scholar
• Harding S. The human pharmacology of fluticasone propionate. Respiratory Med 1990;84: 25–9
   PubMed Web of Science ®Google Scholar
• Martin BG, Ratner PH, Hampel FC, . Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy asthma Proc 2007;28: 216–22
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner P, Zieglmayer R, . The effects of repeated daily doses of fluticasone propionate aqueous nasal spray (FPANS), an intranasal corticosteroid, and intranasal GW559090 (IN9090), a selective VLA-4 integrin inhibitor, on seasonal allergic rhinitis symptoms elicited by controlled pollen exposure in the Vienna Challenge Chamber (VCC). Ann Allergy Asthma Immunol 2005;94: 104[Abstract]
   Google Scholar
• Horak F, Stübner P, Zieglmayer R, . Comparison of the effect of desloratadine 5 mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003;58: 481–5
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner UP, Zieglmayer R, . Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109;6: 956–61
   Web of Science ®Google Scholar
• Horak F, Zieglmayer PU, Zieglmayer R, . Levocetirizine has a longer duration of action than fexofenadine after single administration. Br J Clin Pharmacol 2005;60: 24–31
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner P, Zieglmayer R, . Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125: 73–9
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer UP, Zieglmayer R, . Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis. A pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin 2006;22: 151–7
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner P, Zieglmayer R, . Clinical study of the therapeutic efficacy and safety of emedastine difumarate versus cetirizine in the treatment of seasonal allergic rhinitis. Drug Res 2004;54: 666–72
   PubMed Web of Science ®Google Scholar
• Horak F, Unkauf M, Beckers C, . Efficacy and tolerability of intranasally applied dimetindene maleate solution versus placebo in the treatment of seasonal allergic rhinitis. Drug Research 2000;50: 1099–110
   Web of Science ®Google Scholar
• Stübner P, Zieglmayer R, Horak F. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC). Curr Med Res Opin 2004;20: 891–902
   PubMed Web of Science ®Google Scholar
• Horak F, Stübner P, Berger UE, . Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998;8: 165–71
   PubMed Web of Science ®Google Scholar
• Horak F, Toth J, Hirschwehr R, . Effect of continuous allergen challenge on clinical symptoms and mediator release in dust-mite-allergic patients. Allergy 1998;53: 68–72
   PubMed Web of Science ®Google Scholar
• Horak F, Jäger S, Nirnberger G, . Dose-related control of allergic rhinitis symptoms by a H1-receptor antagonist. Finding the proper doses [correction of dosis] of dimethindene maleate in patients with allergic rhinitis. Int Arch Allergy Immunol 1994;103: 298–302
   PubMed Web of Science ®Google Scholar
• Horak F, Toth J, Jäger S, . Effects of H1-receptor antagonists on nasal obstruction in atopic patients. Allergy 1993;48: 226–9
   PubMed Web of Science ®Google Scholar
• Horak F, Jäger S, Berger U. Onset and duration of the effects of three antihistamines in current use – astemizole, loratadine and terfenadine forte – studied during prolonged, controlled allergen challenges in volunteers. J Int Med Res 1992;20: 422–34
   PubMed Web of Science ®Google Scholar